RUNX2 and prostate cancer: Recently, Wang et al. reported that, in contrast to RUNX2, low ATF3 (activating transcription factor 3) expression level is significantly associated with poor survival of prostate cancer patients, indicating that ATF3 might serve as a tumor suppressor against prostate cancer [150].